{
    "Symbol": "NVO",
    "AssetType": "Common Stock",
    "Name": "Novo Nordisk A/S",
    "Description": "Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.",
    "CIK": "353278",
    "Exchange": "NYSE",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "NOVO ALLE DK 2880, BAGSVAERD DENMARK, DK",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2023-03-31",
    "MarketCapitalization": "369639621000",
    "EBITDA": "86855000000",
    "PERatio": "40.34",
    "PEGRatio": "2.03",
    "BookValue": "4.438",
    "DividendPerShare": "0",
    "DividendYield": "0.011",
    "EPS": "4.09",
    "RevenuePerShareTTM": "10.42",
    "ProfitMargin": "0.325",
    "OperatingMarginTTM": "0.433",
    "ReturnOnAssetsTTM": "0.228",
    "ReturnOnEquityTTM": "0.835",
    "RevenueTTM": "188290007000",
    "GrossProfitTTM": "148506000000",
    "DilutedEPSTTM": "4.09",
    "QuarterlyEarningsGrowthYOY": "0.412",
    "QuarterlyRevenueGrowthYOY": "0.27",
    "AnalystTargetPrice": "179.9",
    "TrailingPE": "40.34",
    "ForwardPE": "31.15",
    "PriceToSalesRatioTTM": "1.785",
    "PriceToBookRatio": "27.9",
    "EVToRevenue": "1.779",
    "EVToEBITDA": "3.704",
    "Beta": "0.296",
    "52WeekHigh": "172.97",
    "52WeekLow": "94.26",
    "50DayMovingAverage": "161.34",
    "200DayMovingAverage": "141.53",
    "SharesOutstanding": "2240240000",
    "DividendDate": "2023-04-04",
    "ExDividendDate": "2023-03-24"
}